Smithbridge Asset Management Inc. DE Boosts Holdings in Edwards Lifesciences Corporation $EW

Smithbridge Asset Management Inc. DE raised its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 6.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 15,255 shares of the medical research company’s stock after acquiring an additional 989 shares during the period. Smithbridge Asset Management Inc. DE’s holdings in Edwards Lifesciences were worth $1,193,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in EW. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences in the first quarter worth about $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences in the first quarter worth about $27,000. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences in the second quarter worth about $28,000. Global X Japan Co. Ltd. raised its position in shares of Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after acquiring an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC raised its position in shares of Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after acquiring an additional 205 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on EW shares. BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Tuesday, July 29th. Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Barclays upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Finally, Wells Fargo & Company upped their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.4%

EW stock opened at $72.66 on Friday. The company has a market cap of $42.66 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 3.50 and a beta of 1.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $83.00. The firm has a 50-day moving average of $77.61 and a two-hundred day moving average of $76.14.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.